Sarah Halford

3.6k total citations
51 papers, 2.5k citations indexed

About

Sarah Halford is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Sarah Halford has authored 51 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 17 papers in Molecular Biology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Sarah Halford's work include Genetic factors in colorectal cancer (15 papers), Cancer Genomics and Diagnostics (11 papers) and PARP inhibition in cancer therapy (8 papers). Sarah Halford is often cited by papers focused on Genetic factors in colorectal cancer (15 papers), Cancer Genomics and Diagnostics (11 papers) and PARP inhibition in cancer therapy (8 papers). Sarah Halford collaborates with scholars based in United Kingdom, Finland and United States. Sarah Halford's co-authors include Ian Tomlinson, Andrew Rowan, Walter F. Bodmer, Rebecca Roylance, Heike Fiegler, Oliver M. Sieber, Lauri A. Aaltonen, Harpreet Wasan, Nigel P. Carter and Patricia Gorman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Sarah Halford

51 papers receiving 2.5k citations

Peers

Countries citing papers authored by Sarah Halford

Since Specialization

Citations

This map shows the geographic impact of Sarah Halford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Halford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Halford more than expected).

Fields of papers citing papers by Sarah Halford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Halford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Halford. The network helps show where Sarah Halford may publish in the future.

Co-authorship network of co-authors of Sarah Halford

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Halford. A scholar is included among the top collaborators of Sarah Halford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Halford. Sarah Halford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers 2023 ·Annals of Oncology ·Gary Middleton, Lynley V. Marshall, Lucinda Billingham, Kate Duffus, Alastair Greystoke, Louise Carter, Martin Förster, Natalie Cook, Darren Hargrave, Sarah Danson, Patricia Roxburgh, Andrew D. Beggs, Anshuman Chaturvedi, Louis Chesler, (unknown), Caroline Dive, Dominic G. Rothwell, Jacqui Gath, Sarah Halford, Matthew Krebs	1
2	A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours 2018 ·Annals of Oncology ·Ruth Plummer, Sarah Halford, Paul S. Jones, Stephen R. Wedge, Sandra Hirschberg, Gareth J. Veal, Geoffrey S. Payne, Maxime Chénard-Poirier, Hector C. Keun, Udai Banerji	24
3	A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma 2018 ·British Journal of Cancer ·Natalie Cook, Bristi Basu, D. M. Smith, Aarthi Gopinathan, Jonathan J. Evans, William P. Steward, Daniel H. Palmer, David Propper, Balaji Venugopal, (unknown), Alan Anthoney, Lisa V. Hampson, Michael Nebozhyn, David A. Tuveson, (unknown), Helen Turner, (unknown), Sarah Halford, Duncan I. Jodrell	96
4	A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424 2018 ·British Journal of Cancer ·Victoria K. Woodcock, Sally Clive, Richard H. Wilson, Vicky M. Coyle, Michael R.L. Stratford, Lisa K. Folkes, Richard Eastell, Claire Barton, Paul S. Jones, (unknown), Helen Turner, Sarah Halford, Adrian L. Harris, Mark R. Middleton	10
5	ACTR-16. RESULTS OF THE OPARATIC TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS WITH RELAPSED GLIOBLASTOMA (GBM) 2017 ·Neuro-Oncology ·Anthony J. Chalmers, Garth Cruickshank, Laurence Dunn, Sara Erridge, Lisa Godfrey, Christopher Herbert, Sarah Jefferies, Juanita Lopez, Catherine McBain, Marc Pittman, (unknown), Colin Watts, (unknown), Sarah Halford	14
6	A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma 2016 ·Clinical Cancer Research ·R. Rampling, (unknown), Paul Mulholland, Allan James, (unknown), Christopher Twelves, Catherine McBain, Sarah Jefferies, Alan Jackson, William Stewart, Juha Lindner, (unknown), Norbert Hilf, (unknown), (unknown), (unknown), Oliver Schoor, Harpreet Singh‐Jasuja, Sarah Halford, (unknown)	122
7	A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors 2016 ·Annals of Oncology ·Simon Pacey, Fiona Blackhall, Javier García-Corbacho, (unknown), Alberto Fusi, Sanjeev Kumar, (unknown), (unknown), (unknown), Sarah Halford, (unknown), (unknown), Susan Wan, Denis Talbot	1
8	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer 2016 ·British Journal of Cancer ·Yvette Drew, Jonathan A. Ledermann, Geoff Hall, Daniel Rea, Rosalind Glasspool, Martin Highley, Gordon C. Jayson, Julieann Sludden, J. C. Murray, David Jamieson, Sarah Halford, Gary D Acton, (unknown), Raffaella Mangano, Alan V. Boddy, Nicola J. Curtin, Ruth Plummer	126
9	Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience 2016 ·European Journal of Cancer ·Han Hsi Wong, Claire Barton, Gary D Acton, (unknown), Sarah Halford	15
10	Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? 2015 ·The Lancet Oncology ·Han Hsi Wong, Sarah Halford	15
11	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study 2014 ·Clinical Cancer Research ·Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell‐Hewson, Guy Makin, Sarah Halford, Gary D Acton, Philip Ross, (unknown), Victoria Lock, Ana Isabel Enríquez Rodríguez, John F. Lyons, Alan V. Boddy, (unknown), Murray Yule, Darren Hargrave	39
12	A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer 2014 ·British Journal of Cancer ·Rosalind Glasspool, Robert Brown, Martin Gore, Gordon Rustin, Iain A. McNeish, Richard H. Wilson, (unknown), James Paul, Melanie Mackean, Geoff Hall, Hani Gabra, Sarah Halford, Julie Walker, Kim Appleton, (unknown), Stan B. Kaye	84
13	Most low‐level microsatellite instability in colorectal cancers can be explained without an elevated slippage rate 2008 ·The Journal of Pathology ·Trevor A. Graham, Sarah Halford, (unknown), IPM Tomlinson	12
14	Refining Molecular Analysis in the Pathways of Colorectal Carcinogenesis 2005 ·Clinical Gastroenterology and Hepatology ·Andrew Rowan, Sarah Halford, Michelle Gaasenbeek, Zoe Kemp, Oliver M. Sieber, Emmanouil Volikos, (unknown), Heike Fiegler, Nigel Carter, Ian Talbot, Andrew Silver, Ian Tomlinson	43
15	Array Comparative Genomic Hybridization Analysis of Colorectal Cancer Cell Lines and Primary Carcinomas 2004 ·Cancer Research ·(unknown), Heike Fiegler, Andrew Rowan, Sarah Halford, David Bicknell, Walter F. Bodmer, Ian Tomlinson, Nigel P. Carter	157
16	Germline Mutations but Not Somatic Changes at the MYH Locus Contribute to the Pathogenesis of Unselected Colorectal Cancers 2003 ·American Journal Of Pathology ·Sarah Halford, Andrew Rowan, Lara Lipton, Oliver M. Sieber, Kevin Pack, Huw Thomas, Shirley V. Hodgson, Walter F. Bodmer, Ian Tomlinson	102
17	Authors' reply 2003 ·The Journal of Pathology ·Ian Tomlinson, Sarah Halford, Lauri A. Aaltonen, Nicholas J. Hawkins, Robyn L. Ward	1
18	Diamorphine or morphine for ischaemic cardiac chest pain 2003 ·Emergency Medicine Journal ·Sarah Halford	1
19	A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma 2001 ·Annals of Oncology ·Sarah Halford, Desmond Yip, Christos S. Karapetis, A. H. Strickland, (unknown), H.T. Khawaja, Peter Harper	51
20	Adjuvant mitozantrone chemotherapy in advanced prostate cancer 2000 ·British Journal of Urology ·(unknown), Sarah Halford, Anne Rigg, Rebecca Roylance, Marcus Lynch, Jonathan Waxman	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact